MedTrace Logo

Effect of H. Pylori Eradication on the Fate of H. Pylori-associated Gastric Polyp

NCT03065868 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2019-09-26

No results posted yet for this study

Summary

Evaluation of the effect of H. pylori eradication on regression of H. pylori-related gastric polyp (Ranomized controlled trial)

1. Study design: open labeled RCT
2. Study group H. pylori eradication group (N=17), non-eradication group (N=15)
3. Treatment plan

1. Baseline EGD

: 0.3-1cm sized polyp - bx \& CLO test (antrum \& body)

==\> if H. pylori positive and eligible patients, randomization
2. Triple therapy
3. UBT (4week after eradication)
4. Follow-up EGD: gross finding, CLO test
4. Evaluation of polyp regression

1. disappear
2. regression over 50% (size, number)
3. no change or increase (size, number)

Conditions

  • Gastric Polyp
  • Helicobacter Pylori Infection

Interventions

DRUG

H. pylori eradication (Amoxaxillin, Lanston, Clarithromycin)

H. pylori eradication (Triple Therapy) as first line treatment if eradication failure, quadruple therpy will be provided as 2nd line treatment

Sponsors & Collaborators

  • Kyungpook National University Hospital

    lead OTHER

Principal Investigators

  • Su Youn Y Nam, MD, PhD · Kyungpook National University Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-12-09
Primary Completion
2019-04-30
Completion
2019-04-30

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03065868 on ClinicalTrials.gov